CJC-1295 With DAC

CJC-1295 with DAC is a synthetic peptide of the growth-hormone-releasing hormone (GHRH) analog class, supplied in lyophilized form for reconstitution in a laboratory setting. The "DAC" designation refers to a Drug Affinity Complex modification, which is reported to extend the molecule's circulating half-life relative to non-DAC GHRH analogs. It is intended strictly for laboratory research and professional investigational use and is not approved by the FDA for therapeutic use. This reference is written for licensed practitioners ordering through a wholesale platform and is provided as professional reference information rather than patient-facing marketing.

The compound is studied in preclinical and laboratory literature within the broader area of growth hormone axis signaling and somatotropic research. Any references to observed effects are drawn from the research context, and individual results vary.

• Investigated in preclinical literature for its role as a GHRH analog within growth hormone secretion research models
• Studied in laboratory settings for its extended half-life properties relative to non-DAC GHRH analogs
• Examined in research contexts exploring pulsatile versus sustained somatotropic axis signaling
• Reported in research literature as a tool compound for studying GH and IGF-1 pathway dynamics
• Referenced in investigational work on receptor-binding behavior of long-acting peptide analogs

For research handling reference: the lyophilized peptide is typically reconstituted with bacteriostatic water (or another sterile diluent appropriate to the laboratory protocol), adding the diluent slowly against the vial wall and gently swirling rather than shaking to preserve peptide integrity. Unreconstituted vials are generally stored frozen or refrigerated and protected from light, heat, and moisture; once reconstituted, the solution is commonly kept refrigerated, shielded from light, and used within the working window indicated by the laboratory's stability practices. Avoid repeated freeze-thaw cycles and inspect the solution for clarity before use. All clinical and investigational protocols, including any reconstitution concentrations, are determined solely by the licensed ordering provider at their professional discretion; this is reference information only and not medical advice.

A per-lot Certificate of Analysis, HPLC purity profile, and mass-spectrometry verification are available on request for this product. Ask your account manager for the current lot documentation.

In the research literature, CJC-1295 with DAC is described as an analog of growth-hormone-releasing hormone that is proposed to bind GHRH receptors on somatotroph cells of the anterior pituitary, where it is studied for its capacity to stimulate the synthesis and release of growth hormone. The DAC (Drug Affinity Complex) modification is reported to allow the molecule to bind reversibly to circulating serum albumin, which preclinical work associates with reduced enzymatic degradation and a prolonged plasma half-life compared with unmodified GHRH analogs. This extended exposure is investigated for its proposed influence on downstream growth hormone and IGF-1 signaling within experimental models. Mechanistic descriptions remain research-framed, and individual results vary.